Could high-dose-rate monotherapy survive beyond stereotactic ablative radiotherapy era for clinically localized prostate cancer?

Radiother Oncol. 2022 Feb:167:97-98. doi: 10.1016/j.radonc.2021.12.015. Epub 2021 Dec 20.

Authors

Hideya Yamazaki¹, Gen Suzuki², Norihiro Aibe², Koji Masui², Ken Yoshida³, Satoaki Nakamura³

Affiliations

¹ Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan. Electronic address: hideya10@hotmail.com.
² Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan.
³ Department of Radiology, Kansai Medical University, Hirakata, Japan.

PMID: 34942282
DOI: 10.1016/j.radonc.2021.12.015

No abstract available

Keywords: High dose rate brachytherapy; Prostate cancer; Stereotactic ablative radiotherapy; Ultrahypofractionation.

Publication types

Letter
Comment

MeSH terms

Humans
Male
Prostatic Neoplasms* / radiotherapy
Prostatic Neoplasms* / surgery
Radiosurgery*